Heart failure & cardiomyopathies
Tirzepatide Reduces Left Ventricular (LV) Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT Cardiac Magnetic Resonance (CMR) Substudy
Primary result · LV massResult — go to the resultDifference −11 g 95% CI −19 to −4Authors' conclusion
The CMR substudy of the SUMMIT trial demonstrated that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared with placebo, and the change in LV mass paralleled weight loss.
Study context
- Population
- Patients with obesity-related heart failure with preserved ejection fraction (HFpEF)106 analysed
- Participants
- 175 patients
- Comparison
- Tirzepatide vs placebo
- Tirzepatiden = 50
- Placebon = 56reference
- Primary endpoint
- Between-group changes in LV mass (CMR)
- Follow-up
- 52 weeks
Methodological detailsCMR substudy, placebo-controlled
- CMR substudy
- Placebo-controlled
Primary result
LV mass
Difference
−11 g
95% CI −19 to −4
P = 0.004
Tirzepatidevs Placebo
difference −11 g (95% CI −19 to −4); P = 0.004
As reported in the abstract
Further findings
| Outcome | Difference (mL) (95% CI) | P value | |
|---|---|---|---|
| Paracardiac (epicardial plus pericardial) adipose tissue · 52 weeksPlacebo-corrected decrease | −45 (−69 to −22) | P < 0.001 | |
| −100−50050Difference, mL (linear scale) |
Correlates of LV mass change (tirzepatide)
- Correlated with change in body weight
- P < 0.02
- Tended to correlate with changes in waist circumference and BP
- P = 0.06
- Correlated with changes in LV end-diastolic volume and left atrial end-diastolic and end-systolic volumes
- P < 0.03
Original publication
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. J Am Coll Cardiol. Published 18 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →